The US regulator has cleared Cara Therapeutics' Korsuva (difelikefalin) as an injectable treatment for chronic itching, also known as pruritus, in these patients after a priority review.

The drug – which is injected three times weekly – was approved in the US last year as Korsuva, and is due to be launched there this month. It acts as an opioid agonist, targeting the kappa ...